Literature DB >> 25079444

Adverse drug reaction reports of patients and healthcare professionals-differences in reported information.

Leàn Rolfes1, Florence van Hunsel, Sarah Wilkes, Kees van Grootheest, Eugène van Puijenbroek.   

Abstract

PURPOSE: This study aims to explore the differences in reported information between adverse drug reaction (ADR) reports of patient and healthcare professionals (HCPs), and, in addition, to explore possible correlation between the reported elements of information.
METHODS: This retrospective study compared the reported information between 200 ADR reports of patients and HCPs. Reports were rendered anonymous and scored for the presence or absence of predefined elements of information. These elements can be objective (e.g. start date of the ADR) or subjective (e.g. the impact or severity of the ADR). A two-sided Pearson's Chi-square test was used to detect statistically significant differences in the reported information. A Bonferroni correction was used to correct for multiple comparisons. Correlation between the elements of information was explored using categorical principal components analysis (CATPCA).
RESULTS: Overall, HCPs had a higher score for the presence of objective and patients for subjective elements of information. Elements that were statistically significant more often reported by patients are the impact of the ADR and the patient's weight and height. HCPs statistically significant more often reported the medical history and the route of administration of the drug. CATPCA showed four clusters of elements of information that have fair correlation.
CONCLUSIONS: This study demonstrates the differences in reported information between ADR reports of patients and HCPs. Patient reports are more focused on patient-related information and the impact of the reported ADRs, whereas reports from HCPs provide more clinically related information.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  adverse drug reactions (ADRs); patient reporting; pharmacoepidemiology; pharmacovigilance

Mesh:

Substances:

Year:  2014        PMID: 25079444     DOI: 10.1002/pds.3687

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  25 in total

1.  Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.

Authors:  Cristiano Matos; Florence van Hunsel; João Joaquim
Journal:  Eur J Clin Pharmacol       Date:  2015-05-26       Impact factor: 2.953

Review 2.  ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.

Authors:  Linda Härmark; Florence van Hunsel; Birgitta Grundmark
Journal:  Drug Saf       Date:  2015-04       Impact factor: 5.606

3.  Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data".

Authors:  Farid Kheloufi; Anne Default; Frank Rouby; Olivier Blin; Joelle Micallef
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

4.  Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?

Authors:  Kristian Svendsen; Kjell H Halvorsen; Solveig Vorren; Hilde Samdal; Beate Garcia
Journal:  Eur J Clin Pharmacol       Date:  2017-12-18       Impact factor: 2.953

5.  Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.

Authors:  George Tsey Sabblah; Delese Mimi Darko; Hudu Mogtari; Linda Härmark; Eugène van Puijenbroek
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

Review 6.  The value of patient reporting to the pharmacovigilance system: a systematic review.

Authors:  Pedro Inácio; Afonso Cavaco; Marja Airaksinen
Journal:  Br J Clin Pharmacol       Date:  2016-10-12       Impact factor: 4.335

7.  The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.

Authors:  Genaro Castillon; Francesco Salvo; Yola Moride
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

8.  Survey of patients' experiences and their certainty of suspected adverse drug reactions.

Authors:  Jarernsiripornkul Narumol; Patsuree Arunrot; Janet Krska
Journal:  Int J Clin Pharm       Date:  2015-01-10

9.  The Role of European Patient Organizations in Pharmacovigilance.

Authors:  Cristiano Matos; Gerda Weits; Florence van Hunsel
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

10.  Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?

Authors:  Linda Härmark; June Raine; Hubert Leufkens; I Ralph Edwards; Ugo Moretti; Viola Macolic Sarinic; Agnes Kant
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.